These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 12499223)

  • 1. Comparison of linezolid activities under aerobic and anaerobic conditions against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
    Gunderson BW; Ibrahim KH; Peloquin CA; Hovde LB; Rotschafer JC
    Antimicrob Agents Chemother; 2003 Jan; 47(1):398-9. PubMed ID: 12499223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in vitro activity of linezolid and five other antimicrobials against nosocomial isolates of methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis and vancomycin-resistant Enterococcus faecium.
    Metallidis S; Chatzidimitriou M; Nikolaidis P; Tsona A; Bisiklis A; Kollaras P; Tsiakiri E; Koumentaki E; Alexiou-Daniel S
    J Chemother; 2003 Oct; 15(5):442-8. PubMed ID: 14603881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
    Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
    Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria.
    Yong D; Yum JH; Lee K; Chong Y; Choi SH; Rhee JK
    Antimicrob Agents Chemother; 2004 Jan; 48(1):352-7. PubMed ID: 14693566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro analysis of resistance selection by linezolid in vancomycin-susceptible and -resistant Enterococcus faecalis and Enterococcus faecium.
    Allen GP; Bierman BC
    Int J Antimicrob Agents; 2009 Jul; 34(1):21-4. PubMed ID: 19243921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.
    Rybak MJ; Cappelletty DM; Moldovan T; Aeschlimann JR; Kaatz GW
    Antimicrob Agents Chemother; 1998 Mar; 42(3):721-4. PubMed ID: 9517963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [In vitro activity of linezolid/ertapenem combination in resistant gram-positive bacteria].
    Eraç B; Taşli H; Ermertcan S; Cilli F; Limoncu MH
    Mikrobiyol Bul; 2009 Jan; 43(1):45-51. PubMed ID: 19334379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model.
    LaPlante KL; Rybak MJ; Leuthner KD; Chin JN
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1298-303. PubMed ID: 16569844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linezolid pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model.
    Strukova EN; Smirnova MV; Vostrov SN; Lubenko IY; Firsov AA; Zinner SH; Portnoy YA
    Int J Antimicrob Agents; 2009 Mar; 33(3):251-4. PubMed ID: 19095420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative activity of linezolid against staphylococci and enterococci isolated in Italy.
    Stefani S; Mezzatesta ML; Tempera G; Debbra E; Schito AM; Nicoletti G; Marchére A
    Clin Microbiol Infect; 2002 Jun; 8(6):368-72. PubMed ID: 12084106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-antibiotic growth suppression of linezolid against Gram-positive bacteria.
    Munckhof WJ; Giles C; Turnidge JD
    J Antimicrob Chemother; 2001 Jun; 47(6):879-83. PubMed ID: 11389123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of linezolid against levofloxacin-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in Hong Kong.
    Ho PL; Ng TK; Yung RW; Que TL; Yip EK; Tse CW; Yuen KY
    J Antimicrob Chemother; 2001 Oct; 48(4):590-2. PubMed ID: 11581246
    [No Abstract]   [Full Text] [Related]  

  • 13. [In vitro susceptibility to linezolid in methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus strains].
    Efe S; Sinirtaş M; Ozakin C
    Mikrobiyol Bul; 2009 Oct; 43(4):639-43. PubMed ID: 20084917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp.
    Drago L; Nicola L; De Vecchi E
    Clin Microbiol Infect; 2008 Jun; 14(6):608-11. PubMed ID: 18397336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo activities of linezolid alone and combined with vancomycin and imipenem against Staphylococcus aureus with reduced susceptibility to glycopeptides.
    Ribes S; Pachón-Ibáñez ME; Domínguez MA; Fernández R; Tubau F; Ariza J; Gudiol F; Cabellos C
    Eur J Clin Microbiol Infect Dis; 2010 Nov; 29(11):1361-7. PubMed ID: 20680368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey.
    Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L
    Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.
    Sweeney MT; Zurenko GE
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1902-6. PubMed ID: 12760865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci.
    Livermore DM; Warner M; Mushtaq S; North S; Woodford N
    Antimicrob Agents Chemother; 2007 Mar; 51(3):1112-4. PubMed ID: 17210773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of linezolid in an in vitro pharmacokinetic-pharmacodynamic model using different dosages and Staphylococcus aureus and Enterococcus faecalis strains with and without a hypermutator phenotype.
    Ba BB; Arpin C; Bikie Bi Nso B; Dubois V; Saux MC; Quentin C
    Antimicrob Agents Chemother; 2010 Apr; 54(4):1443-52. PubMed ID: 20100878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo pharmacodynamics of a new oxazolidinone (linezolid).
    Andes D; van Ogtrop ML; Peng J; Craig WA
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3484-9. PubMed ID: 12384354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.